source
- Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trialEli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and e…
- Eli Lilly's retatrutide shows strong weight loss but no clear heart risk reduction in Phase 3 trialEli Lilly released new data from a Phase 3 trial of retatrutide, its next‑generation obesity drug. The study enrolled nearly 2,000 participants with severe obesity and existing heart disease, some…